Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of AJM300 in Subjects With Hepatic Impairment
jRCT2080224743Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of firategrast in Cirrhosis (2 arms), sponsored by EA Pharma Co., Ltd. Primary endpoints: Pharmacokinetics of AJM300 active metabolites and Safety and tolerability. Started Jun 2019; status: completed.
02
Drugs
firategrast
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on jRCT2080224743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224743.